Department of Biotechnology, National Institute of Technology, Warangal 506004, Telangana, India.
Department of Biotechnology, National Institute of Technology, Warangal 506004, Telangana, India.
Infect Genet Evol. 2020 Nov;85:104464. doi: 10.1016/j.meegid.2020.104464. Epub 2020 Jul 15.
Ebola virus (EBOV) is a rare but fatal disease that has been a burden to mankind for over 40 years. EBOV exhibits several symptoms including severe bleeding, organ failure and if left untreated causes death. It is assumed that fruit bats of the Pteropodidae family are natural hosts for the virus. Over the years, there has been no effective vaccine that can confer immunity to this virus. Considering the necessity of a vaccine against EBOV, this study to develop a multi-epitope subunit vaccine for the EBOV using the immunoinformatics approach was conducted. The construct was designed using structural and non-structural proteins of EBOV. Class I and Class II MHC epitopes were predicted and linked along with β defensin and compatible linkers. B-cell linear epitopes were also assessed and the physiological parameters of the vaccine were determined. The vaccine was capable of administration to humans and also is capable of an immune response. The vaccine was modeled further and affinity towards the TLR4 receptor was studied by docking and simulation for 20 ns. The trajectory analysis high affinity between the vaccine and the construct with an average hydrogen bond of 18. For ease of purification, the vaccine construct was ligated into pET28a(+) vector with His-tag. Concluding from the results, the vaccine construct has the potentiality to help develop immunity against the Ebola virus. Furthermore, experimental and immunological investigations will be required to verify the feasibility of the multi-epitope subunit construct as a commercial vaccine.
埃博拉病毒（EBOV）是一种罕见但致命的疾病，已经困扰人类超过 40 年。EBOV 表现出多种症状，包括严重出血、器官衰竭，如果不治疗，会导致死亡。据推测，翼手目蝙蝠科的蝙蝠是该病毒的自然宿主。多年来，一直没有有效的疫苗能够对这种病毒产生免疫力。鉴于对埃博拉病毒疫苗的必要性，本研究采用免疫信息学方法，开发了一种针对 EBOV 的多表位亚单位疫苗。该构建体使用 EBOV 的结构和非结构蛋白设计。预测了 I 类和 II 类 MHC 表位，并与β防御素和相容接头连接。还评估了 B 细胞线性表位，并确定了疫苗的生理参数。该疫苗可用于人类，并能引起免疫反应。进一步对疫苗进行建模，并通过对接和模拟研究了 20ns 内与 TLR4 受体的亲和力。轨迹分析表明，疫苗与构建体之间具有高亲和力，平均氢键为 18。为了便于纯化，将疫苗构建体与 His 标签连接到 pET28a(+)载体上。从结果得出结论，该疫苗构建体有可能帮助开发针对埃博拉病毒的免疫力。此外，还需要进行实验和免疫学研究，以验证多表位亚单位构建体作为商业疫苗的可行性。
